Blog

• Four presentations sustaining the relevance of biotherapy monitoring using LISA TRACKER tests
• Oral Presentation by Prof. X. Roblin on the predictive potential of pharmacological level testing associated with other biomarkers
• Strong interest and increasing use of biotherapy monitoring tools by the scientific community

Croissy-Beaubourg and Montpellier, March 23, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that four abstracts sustaining the relevance of biotherapy monitoring were presented at the Francophone Gastroenterology, Liver-Disease and Digestive Cancer (JFHOD) 2015 meeting in Paris, March 19-22, 2015.

« More and more physicians show interest in LISA TRACKER, our biotherapy monitoring range, and are using our tests in clinical trials and in routine care. This endorsement by the medical community is critical for Theradiag and for the further development of LISA TRACKER sales, as doctors and clinicians are the first prescribers of our tests” commented Michel Finance, Chief Executive Officer of Theradiag.

These four presentations underline the main advantages of biotherapy monitoring with theranostics kits:

–          Improvement of the therapeutic strategy through the evaluation of biological parameters ;

–          Identification and prevention of the loss of response to treatment ;

–          Prediction of treatment response ;

–          Reduction of healthcare costs

More specifically, the oral presentation by Prof. Roblin is the first demonstration of the predictive role played by pharmacological and inflammation biomarkers in Crohn’s Disease. According to this study, relapses of patients in clinical remission were anticipated in 95% of cases over 12 months through the dosing of residual treatment levels with LISA TRACKER kits associated with the measure of fecal calprotectin.

Oral Presentation by Professor X. Roblin[1]

Developing a non-invasive, predictive, score of clinical pathway in Crohn’s Disease Patients treated with infliximab, X. Roblin, S. Paul, G. Duru, L. Clavel, J.-M. Phelip, E. Del Tedesco, L. Peyrin-Biroulet – C.O.102.

Posters[2] 

Anti-TNFα-optimization: measuring residual levels of anti-TNFα leads to significant reductions in healthcare costs while maintaining at least the same level of clinical efficacy as current therapeutic strategies – X. Roblin, A. Attar, M. Lamure, B. Savarieau, P. Brunel, G. Duru, L. Peyrin-Biroulet – Poster 36.

Variation of the cut-off levels of residual infliximab based on the chosen efficacy criteria in IBD- X. Roblin, E. Del Tedesco, N. Bouarioua, L. Rinaldi, J.-M. Phelip, S. Paul – Poster 50.

Feasibility and relevance of anti-TNFα dosing in feces of IBD patients who are losing response to treatment : a preliminary study – S. Paul, E. Del Tedesco, C. Jarlot, L. Rinaldi, JM. Phelip, N. Bouarioua, W. Dronne, X. Roblin – Poster 168.

All of the above-mentioned studies used LISA TRACKER kits to measure pharmacological levels.

Abstracts of these studies are available in French in the JFHOD 2015 catalogue: http://www.jfhod.com/data/upload/files/Livre-resumes-JFHOD2015.pdf.

About JFHOD 2015

The Francophone Days of Gastroenterology, Liver-Disease and Digestive Cancer is the meeting of reference for GI diseases and cancers in the French-speaking world, and the second largest European meeting for these diseases. The JFHOD are sponsored by the French National Society for Gastroenterology and the French Association for Continuing Association in Gastroenterology and Liver Diseases.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer and HIV/AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.

For more information about Theradiag, please visit our website: www.theradiag.com